Novel Perspectives for Glutamatergic Strategies, Psychedelics and Antipsychotic Augmentation in Treatment Resistant Depression: A Narrative Review
Clinical Neuropsychopharmacology and Addiction · 25.09.2025 · 1 (1)
DOI: 10.53941/cna.2025.100006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Neuropsychopharmacology and Addiction, online erschienen am 25.09.2025. Verfasst von Clara Cavallotto und 14 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Introduction
Treatment-Resistant Depression (TRD) affects approximately 30–50% of patients with Major Depressive Disorder (MDD) who fail to respond to at least two adequate antidepressant trials. This condition presents substantial clinical and functional challenges, and no universally accepted treatment algorithm currently exists. Emerging therapeutic strategies, particularly glutamatergic modulators and psychedelics, have shown promising results in managing TRD.
Methods
We conducted a narrative review using PubMed and Scopus with the query “(treatment resistant depression OR TRD) AND (glutamatergic OR glutamate OR psychedelic OR psilocybin OR antipsychotic augmentation) NOT (review OR animal OR mouse).” After applying inclusion/exclusion criteria, 60 articles were selected.
Results
The most frequently studied treatments (43 studies) are glutamatergic agents, particularly intravenous ketamine and intranasal esketamine, which have consistently demonstrated rapid and clinically meaningful reductions in depressive symptoms. Augmentation with atypical antipsychotics also showed effectiveness for partial responders. Psychedelic-assisted therapies yielded sustained antidepressant benefits and modulated biomarkers such as BDNF and inflammatory markers. Discussion and Conclusion: The findings support a potential paradigm shift away from traditional monoaminergic-based treatments toward more personalized, mechanism-driven strategies for managing TRD. Ketamine and esketamine offer rapid-onset relief suitable for acute high-risk cases, while augmentation strategies remain valuable for partial responders. Psychedelic interventions, although still experimental, hold promise as adjunctive options. Furthermore, biomarkers and early response predictors may help guide individualized treatment decisions.
Zitieren
APA
Cavallotto, C., Chiappini, S., Miuli, A., d'Andrea, G., Mosca, A., Marrangone, C., Allegretti, R., Panichella, S., D'Attilio, A., Mammarella, G., Persico, L., Santeusanio, A., Tamagnini, G., Pettorruso, M., & Martinotti, G. (2025). Novel Perspectives for Glutamatergic Strategies, Psychedelics and Antipsychotic Augmentation in Treatment Resistant Depression: A Narrative Review. Clinical Neuropsychopharmacology and Addiction, 1(1). https://doi.org/10.53941/cna.2025.100006
Vancouver
Cavallotto C, Chiappini S, Miuli A, d'Andrea G, Mosca A, Marrangone C, et al. Novel Perspectives for Glutamatergic Strategies, Psychedelics and Antipsychotic Augmentation in Treatment Resistant Depression: A Narrative Review. Clinical Neuropsychopharmacology and Addiction. 2025;1(1). doi:10.53941/cna.2025.100006
BibTeX
@article{Cavallotto2025,
author = {Cavallotto, Clara and Chiappini, Stefania and Miuli, Andrea and d'Andrea, Giacomo and Mosca, Alessio and Marrangone, Carlotta and Allegretti, Rita and Panichella, Serena and D'Attilio, Antonio and Mammarella, Giovanna and Persico, Luca and Santeusanio, Alessia and Tamagnini, Gianfranco and Pettorruso, Mauro and Martinotti, Giovanni},
title = {Novel Perspectives for Glutamatergic Strategies, Psychedelics and Antipsychotic Augmentation in Treatment Resistant Depression: A Narrative Review},
journal = {Clinical Neuropsychopharmacology and Addiction},
year = {2025},
volume = {1},
number = {1},
doi = {10.53941/cna.2025.100006}
}
EUVIMED